¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"neutral zone of His"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • proliferation zone
    Áõ½ÄÃþ
  • radiolucent zone
    ¹æ»ç¼±Åõ°ú¿µ¿ª
  • reserve zone
    ¿¹ºñÃþ
  • root entry zone
    ½Å°æ»Ñ¸®ÁøÀÔºÎ
  • sclerotic zone
    °ø¸·´ë
  • temperate zone strain
    ¿Â´ëÁö¿ªÁÖ
  • time zone change syndrome
    (¢¡jet lag syndrome) ºñÇà½ÃÂ÷ÁõÈıº
  • transitional zone
    ÀÌÇàºÎÀ§
  • trigger zone
    ¹ßÅë´ë, ¹æ¾Æ¼è¿µ¿ª, À¯¹ß¿µ¿ª
  • zone
    ±¸¿ª, ´ë,
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inner zone
    ³»´ë(Ò®Óá).
  • polar zone
    ºÐ±Ø´ë.
  • proliferation zone
    Áõ½ÄÃþ
  • pupillary area =p. zone
    µ¿°ø¾ß(ÔÚÍîå¯).
  • pupillary zone
    µ¿°ø¿µ¿ª, µ¿°ø´ë(ÔÚÍîÓá), µ¿°ø¾ß.
  • pupillary zone
    µ¿°øºÎÀ§(ÔÚÍîÓá)
  • radiolucent zone
    ¹æ»ç¼± Åõ°ú ¿µ¿ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • arctic zone
    ºÏ±Ø´ë.
  • autoimmune disease,bypass of t-helper cell(low zone)
    T-º¸Á¶¼¼Æ÷ ³»¼º ¿ìȸ(¡­ÜÍð¾á¬øàÒ±àõéæüß)
  • basement membrane zone
    ±âÀú¸·(Ðñî¼Ø¯) ´ë(Óá)
  • central zone
    Á߽ɴë
  • central zone
    Á߽ɱ¸¿ª.
  • central zone
    Á߽ɱ¸¿ª
  • cervical zone
    ÀڱøñºÎÀ§, ÀڱðæºÎ.
  • chemoreceptor trigger zone
    È­Çмö¿ëü¹æ¾Æ¼è¿µ¿ª
  • chondrogenic zone
    ¿¬°ñ¹ß»ý±¸¿ª
  • climatic zone
    ±âÈÄ´ë(˻̷ËÀ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
NPH   1) Neutral Protamine Hagedorn Insulin
    = Isophane Insulin Susp...
ANRL antihypertensive neutral renomedullary lipid
CANP calcium-activated neutral protease
INLSD ichthyosis and neutral lipid storage disease
LNAA large neutral amino acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
L-HIS L-Histidine
A-H atrio-His
CANP Calcium-activated neutral protease
CANP Calcium-activated neutral proteinase
LNAA Large neutral amino acid
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • odontogenic zone
    Á¶Ä¡Ãþ
  • opaque zone
    ºÒÅõ¸í Ãþ
  • pale(o) °í ¶Ç´Â ±¸¸¦ ¶æÇÏ´Â Á¢µÎ¾î.

    pale-staining zone

    ¿¯Àº ¿°»öÃþ
  • paracortial zone
    °çÇÇÁú °¡½¿»ù ÀÇÁ¸´ë, Èä¼± ÀÇÁ¸´ë
  • proliferative zone
    Áõ½Ä´ë
  • radiolucent zone
    ¹æ»ç¼± Åõ°ú ¿µ¿ª
  • referral zone
    ÀüÀÌ Áö¿ª
    µ¿ÀǾî=reference zone. ÀüÀÌ
  • surface zone
    Ç¥Ãþ, Ç¥Ãþ´ë
  • transitional zone
    ÀÌÇà±Ç
  • transparent zone of caries
    Ä¡¾Æ ¿ì½Ä Åõ¸í´ë
  • trigger zone
    ¹ßÅë ¿µ¿ª, ¹ßÅë´ë, ¹ßÅëÁ¡
    µ¿ÀǾî=trigger
  • zone electrophoresis
    ±¸¿ª Àü±â¿µµ¿¹ý
  • zone glumerulosa
    »ç±¸Ã¼ ¾ç´ë
    ºÎ½Å ÇÇÁúÀÇ °¡Àå ¾ãÀº ¹Ù±ù ÃþÀ¸·Î¼­ ÇǸ·¿¡ Á¢ÇØ ÀÖ´Ù. ºÎ½Å ÇÇÁúÀÇ 10-15%¸¦ Â÷ÁöÇϸç ÀÔ¹æÇü ³»Áö ¿øÁÖ»óÀÇ ¼¼Æ÷µéÀÌ »ª»ªÇÏ°Ô ±ºÁýÀ» ÀÌ·ç°í Àִµ¥, ÇÙÀº ÁøÇÏ°Ô ¿°»öµÇ°í ¼¼Æ÷ÁúÀº ÀûÀ¸¸ç ¼Ò¼öÀÇ Áö¹æ ¼ÒÀûÀ» ÇÔÀ¯Çϰí ÀÖ´Ù.
  • zone of antigen excess
    Ç׿ø °úÀ×´ë
    ºñ±³Àû °í³óµµÀÇ Ç׿ø´ë·Î¼­ ħ°­¹ÝÀÀ¿¡¼­ °¡¿ë¼º º¹ÇÕü°¡ Çü¼ºµÇ¸ç ¹ÝÀÀÀÌ ¾ïÁ¦µÈ´Ù.
  • zone of comfort
    Äè°¨´ë, ÄèÀû´ë
    ¿Âµµ°¡ 13 ~21?C, ½Àµµ°¡ 30~55%ÀΠȯ°æ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
neutral beam injection <radiobiology> This is one of the fundamental plasma heating methods. A particle accelerator is used to create fast ion beams (the particle energies are on the order of 100 keV), the ion beam is then passed through a neutral gas region, where the ions neutralise via charge-exchange reactions with the neutral gas. The neutralised beam is then injected into a magnetically confined plasma. The neutral atoms are unaffected (not confined) by the magnetic field, but ionize as they penetrate into the plasma. The high-energy ions then transfer some of their energy to the plasma particles in repeated collisions, and heat the plasma.
(09 Oct 1997)
neutral buffered formalin fixative A general histologic fixative less likely to leave formalin deposits in tissue than formol-saline fixative.
(05 Mar 2000)
neutral-density filter <equipment> A light-absorbing filter whose absorption spectrum is moderately flat. Depending on the type, the absorption curve is flat primarily in the visible spectral range, or may extend to varying degrees beyond the visible range. For video microscopy, this is an important point since the absorbance may or may not extend into the near-infrared region where the sensitivity of many video image pickup devices is very high.
(05 Aug 1998)
neutral element An element of the zero group of the periodic system comprising the rare gases, He, Ne, Ar, Kr, Xe, Rn.
Synonym: noble element.
(05 Mar 2000)
neutral fat A triester of fatty acids and glycerol (i.e., triacylglycerol).
(05 Mar 2000)
Streptomyces griseus neutral proteinase <enzyme> Component of pronase; included in the group of microbial metalloproteinases EC 3.4.24.4
Chemical name: streptomyces griseus protease 3
Registry number: EC 3.4.24.-
(26 Jun 1999)
neutral lipid storage disease <syndrome> Congenital ichthyosis, leukocyte vacuoles, and variable involvement of other organ systems.
Synonym: neutral lipid storage disease.
(05 Mar 2000)
neutral mutation A mutation that has no selective advantage or disadvantage. Considerable controversy surrounds the question of whether such mutations can exist.
(18 Nov 1997)
neutral occlusion An arrangement of teeth such that the maxillary and mandibular first permanent molars are in normal anteroposterior relation.
Synonym: normal occlusion.
Synonym: neutroclusion.
(05 Mar 2000)
neutral oxide An oxide that is neither an acid nor a base; e.g., water (hydrogen oxide, H2O).
Synonym: indifferent oxide.
(05 Mar 2000)
neutral point The point at which a solution is neither acid nor alkaline (pH 7 at 22°C for aqueous solutions).
(05 Mar 2000)
neutral protease <enzyme> Protease that is optimally active at neutral pH:
See: proteases.
(18 Nov 1997)
neutral reaction PH of 7.00; H+ and OH- ion concentrations equal at 10-7 m at 22°C.
Compare: dissociation constant of water.
(05 Mar 2000)
neutral red <chemical> 3-amino-7-dimethylamino-2-methylphenazine hydrochloride. A vital dye used as an indicator and biological stain. Various adverse effects have been observed in biological systems.
Pharmacological action: dyes, indicators and reagents.
Chemical name: 2,8-Phenazinediamine, N8,N8,3-trimethyl-, monohydrochloride
(12 Dec 1998)
neutral spirits Spirits distilled from suitable raw materials, are 95% ethanol (v/v) that is, at least 190 proof when distilled. Used for blending with straight whiskey and for making gin, cordials, liqueurs, and vodka.
See: alcohol.
Proof spirit, dilute alcohol, specific gravity 0.920, containing 49.5% by weight (57.27% by volume) of C2H5OH at 15.56°C. Originally in Great Britain it was the weakest alcohol that would permit ignition of gunpowder moistened with it. British proof spirit has a specific gravity of 0.9198 and contains 49.2% C2H5OH by weight, or 57.1% by volume at the temperature of 10.56°C.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • foreigntrade zone
    ¿Ü±¹ ¹«¿ª Áö´ë
  • free zone
    ÀÚÀ¯ Áö¿ª
  • gray zone
    À̵µ Àúµµ ¾Æ´Ñ(»óÅÂ);¾Ö¸ÅÇÑ (¹üÀ§);ȸ»ö Áö´ë(ÀÇ)(¾î´À Ãʰ­´ë±¹ÀÇ ¼¼·ÂÇÏ¿¡ ÀÖ´Â Áö ¾Ö¸ÅÇÑ Áö¿ª)
  • isthmian canal zone
    ÆÄ³ª¸¶¿îÇÏ Áö´ë
  • photic region(zone)
    Åõ±¤´ë
  • postal delivery zone
    ¿ìÆí±¸
  • reactor zone
    (¿ì¶ó´½ ±¤»ê µî¿¡¼­ÀÇ)ÇÙ¹ÝÀÀ Áö´ë;ÀÚ¿¬ ¿øÀÚ·Î Áö´ë(¿ÀŬ·Î Çö»ó(Oklo phenomenon)ÀÇ ÈçÀûÀÌ º¸ÀÌ´Â Áö¿ª)
  • safety zone
    ¾ÈÀüÁö´ë
  • takeover zone
    (À°»óÀÇ ¸±·¹ÀÌ¿¡¼­) ¹ÙÅæÀ» ÁÖ°í ¹Þ´Â ±¸¿ª
  • towaway zone
    ÁÖÂ÷±ÝÁö Áö´ë(À§¹Ý Â÷·®Àº ²ø¾î°¨)
  • twilight zone
    Áß°£ Áö´ë;°æ°è ¿µ¿ª;µµ½ÃÀÇ ³ëÈÄÈ­ Áö¿ª
  • zone
    ´ë;Áö´ë;±¸¿ª;µ¿ÀÏ ¿ä±Ý ±¸¿ª
  • zone defense
    Áö¿ª ¹æ¾î
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á